{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:11:11Z","timestamp":1791216671258,"version":"4.1.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"45","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,7]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Psoriasiform rash associated with programmed cell death protein 1 (PD-1) inhibitors typically occurs during the early phase of treatment. However, systemic dissemination triggered by radiotherapy after more than 2 years of immunotherapy is rarely reported. This case aims to highlight the potential for delayed and severe cutaneous immune-related adverse events following combined immunotherapy and radiotherapy, which has significant implications for long-term patient monitoring. Herein, we present a case of a patient with driver-negative lung adenocarcinoma who, after 25 months of tislelizumab monotherapy without cutaneous toxicity, subsequently developed a unique clinical course of psoriasiform rash. The rash initially emerged at the irradiation site (right iliac crest) 1 month after local radiotherapy and progressively disseminated systemically.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>An elderly patient with lung adenocarcinoma, having received tislelizumab for 2 years, developed a right iliac bone metastasis and subsequently underwent stereotactic body radiotherapy (45 Gy in 5 fractions), achieving complete pain relief. However, 1 month post-radiotherapy (25 months after initiating immunotherapy), well-demarcated scaly plaques initially appeared at the irradiation site, followed by centrifugal dissemination to the scalp, trunk, and limbs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Psoriasis as a cutaneous immune-related adverse event.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>PD-1 inhibitor therapy was discontinued, and treatment with oral prednisone (0.5\u2009mg\/kg\/day) combined with topical halometasone was initiated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>After 4 weeks of treatment with oral prednisone (0.5\u2009mg\/kg\/day) and topical halometasone, the psoriasiform rash showed marked regression, with\u2005&gt;\u200580% reduction in erythema and scaling. The patient reported significant relief from pruritus and no new lesions emerged. PD-1 inhibitor therapy remained discontinued, and the patient continued under dermatological surveillance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case supports the \u201ctwo-hit hypothesis\u201d: prolonged PD-1 inhibition establishes a subclinical autoimmune state (first hit), and radiotherapy acts as a second hit, ultimately culminating in systemic toxicity. These findings underscore the necessity for long-term cutaneous surveillance during immunotherapy and rigorous dermatological assessment when combined with radiotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000045550","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T18:02:08Z","timestamp":1762538528000},"page":"e45550","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Radiation-triggered psoriasiform rash with systemic dissemination after prolonged PD-1 inhibitor therapy: A case report"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5115-2280","authenticated-orcid":false,"given":"Mingjun","family":"Wu","sequence":"first","affiliation":[{"name":"Respiratory, 940th Hospital of Joint Logistic Support Force of Chinese People\u2019s Liberation Army, Lanzhou, Gansu Province, China"},{"name":"Department of Plateau Medicine, 940th Hospital of Joint Logistic Support Force of Chinese People\u2019s Liberation Army, Lanzhou, Gansu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Plateau Medicine, 940th Hospital of Joint Logistic Support Force of Chinese People\u2019s Liberation Army, Lanzhou, Gansu Province, China"},{"name":"Central Sterile Supply Department, 940th Hospital of Joint Logistic Support Force of Chinese People\u2019s Liberation Army, Lanzhou, Gansu Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Hou","sequence":"additional","affiliation":[{"name":"Respiratory, 940th Hospital of Joint Logistic Support Force of Chinese People\u2019s Liberation Army, Lanzhou, Gansu Province, China"},{"name":"Department of Plateau Medicine, 940th Hospital of Joint Logistic Support Force of Chinese People\u2019s Liberation Army, Lanzhou, Gansu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haizhen","family":"He","sequence":"additional","affiliation":[{"name":"Respiratory, 940th Hospital of Joint Logistic Support Force of Chinese People\u2019s Liberation Army, Lanzhou, Gansu Province, China"},{"name":"Department of Plateau Medicine, 940th Hospital of Joint Logistic Support Force of Chinese People\u2019s Liberation Army, Lanzhou, Gansu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youcheng","family":"Xie","sequence":"additional","affiliation":[{"name":"Respiratory, 940th Hospital of Joint Logistic Support Force of Chinese People\u2019s Liberation Army, Lanzhou, Gansu Province, China"},{"name":"Department of Plateau Medicine, 940th Hospital of Joint Logistic Support Force of Chinese People\u2019s Liberation Army, Lanzhou, Gansu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6845-2570","authenticated-orcid":false,"given":"Qingliang","family":"Xue","sequence":"additional","affiliation":[{"name":"Respiratory, 940th Hospital of Joint Logistic Support Force of Chinese People\u2019s Liberation Army, Lanzhou, Gansu Province, China"},{"name":"Department of Plateau Medicine, 940th Hospital of Joint Logistic Support Force of Chinese People\u2019s Liberation Army, Lanzhou, Gansu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260729","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/15569527.2022.2034842","article-title":"Adverse cutaneous toxicities by PD-1\/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.","volume":"41","author":"Bhardwaj","year":"2022","journal-title":"Cutan Ocul Toxicol"},{"key":"R2-20260729","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis.","volume":"129","author":"Di Cesare","year":"2009","journal-title":"J Invest Dermatol"},{"key":"R3-20260729","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1158\/1078-0432.CCR-19-2034","article-title":"Radiotherapy and immunotherapy for cancer: from \u201cSystemic\u201d to \u201cMultisite.\u201d.","volume":"26","author":"Arina","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R4-20260729","doi-asserted-by":"crossref","first-page":"e33788","DOI":"10.1097\/MD.0000000000033788","article-title":"Tislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin: a case report.","volume":"102","author":"Wu","year":"2023","journal-title":"Medicine (Baltim)"},{"key":"R5-20260729","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2217\/fon-2020-0989","article-title":"DNA damage response alterations in gastric cancer: knocking down a new wall.","volume":"17","author":"Ricci","year":"2021","journal-title":"Future Oncol"},{"key":"R6-20260729","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.clnesp.2025.03.023","article-title":"Prognostic significance of the cachexia index (CXI) in patients with cancer: A systematic review and meta-analysis.","volume":"68","author":"Bas","year":"2025","journal-title":"Clin Nutr ESPEN"},{"key":"R7-20260729","first-page":"352","article-title":"Associations between \u201cCancer Risk,\u201d \u201cInflammation\u201d and \u201cMetabolic Syndrome\u201d: a scoping review.","volume":"13","author":"Vitale","year":"2024","journal-title":"Biology (Basel)"},{"key":"R8-20260729","doi-asserted-by":"crossref","first-page":"11363","DOI":"10.3390\/ijms231911363","article-title":"Challenges and future trends of hepatocellular carcinoma immunotherapy.","volume":"23","author":"Rizzo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R9-20260729","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.2217\/fon-2021-1647","article-title":"KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer.","volume":"18","author":"Rizzo","year":"2022","journal-title":"Future Oncol"},{"key":"R10-20260729","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.3390\/ijms21186791","article-title":"Psoriasis and antimicrobial peptides.","volume":"21","author":"Takahashi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R11-20260729","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis.","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"R12-20260729","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cell.2017.06.007","article-title":"De Novo epigenetic programs inhibit PD-1 Blockade-mediated T cell rejuvenation.","volume":"170","author":"Ghoneim","year":"2017","journal-title":"Cell"},{"key":"R13-20260729","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/1097-0142(19910201)67:3<588::AID-CNCR2820670311>3.0.CO;2-E","article-title":"Exacerbation of psoriasis after megavoltage irradiation. The Koebner phenomenon.","volume":"67","author":"Schreiber","year":"1991","journal-title":"Cancer"},{"key":"R14-20260729","first-page":"192","article-title":"Psoriasis and radiotherapy: exacerbation of psoriasis following radiotherapy for carcinoma of the breast (the Koebner phenomenon).","volume":"12","author":"Charalambous","year":"2000","journal-title":"Clin Oncol (R Coll Radiol)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045550","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:01:29Z","timestamp":1785351689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":14,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045550","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"2025-06-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}